Skip to main content

Targeting Chemotherapy of Hepatocellular Carcinoma

Arterial Administration of SMANCS/Lipiodol

  • Chapter
Neoplasms of the Liver

Abstract

A number of methods utilize the feeding artery of the tumor for the treatment of hepatocellular carcinoma (HCC); such methods include implantation of an infusion pump, placement of a catheter for injection into the artery, and embolization of the artery with gelatin-gel or microspheres containing anticancer agents. However, very few methods have exploited the use of lipid as a carrier and depository of an anticancer agent. Recently, we developed a procedure in which Lipiodol ultrafluid (Lipiodol) is used as a carrier of anticancer agents for injection into the feeding artery, a significant breakthrough in the treatment of solid tumors. The lipid lymphographic agent, Lipiodol, has been found to be selectively retained in HCC when injected into the hepatic artery [1]. In addition, a lipid contrast medium has various diagnostic applications, as described in this chapter. Anticancer agents, such as styrene maleic acid conjugates of neocarzinostatin (SMANCS) [2,3], mitomycin C (MMC), or aclarubicin (ACR), were dissolved into Lipiodol. As SMANCS/Lipiodol (LPD), MMC/LPD, ACR/LPD, or a mixture of these, these oily anticancer agents were administered by catheterization of the celiac or hepatic artery under X-ray monitor. Anticancer effects and the advantages of this targeting chemotherapy for HCC are described in the succeeding sections of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T, Yokoyama I (1983) Effect of arterial administration of high molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19:1053–1065

    Article  PubMed  CAS  Google Scholar 

  2. Maeda H, Takeshita J, Konamaru R (1979) A lipophylic derivative of neocarzinostatin. Int J Peptide Protein Res 14:81–87

    Article  CAS  Google Scholar 

  3. Maeda H, Ueda M, Morinaga T, Matsumoto T (1985) Conjugation of poly (styrene-co-meleic acid) derivatives to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties. J Med Chem 28:455–461

    Article  PubMed  CAS  Google Scholar 

  4. Folkman J (1974) Tumor angiogenesis. Adv Cancer Res 19:331–359

    Article  PubMed  CAS  Google Scholar 

  5. Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54:2367–2374

    Article  PubMed  CAS  Google Scholar 

  6. Maeda H, Matsumura Y, Oda T, Sasamoto K (1986) Cancer selective macromolecular therapeusis: Tailoring of an antitumor protein drug. In: Whitaker JR, Feeney RE (eds) Protein tailoring for food and medical uses. Dekker, New York, pp 353–382

    Google Scholar 

  7. Maeda H, Takeshita J, Kanamaru R (1979) Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent and water-soluble polymer conjugated protein. Gann 70: 601–606

    PubMed  CAS  Google Scholar 

  8. Maki S, Konno T, Maeda H (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56:751–757

    Article  PubMed  CAS  Google Scholar 

  9. Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, Konno T, Iwamoto S, Ohnishi K, Okuda K (1985) Hepatocellular carcinoma detected by iodized oil. Radiology 154: 19–24

    PubMed  CAS  Google Scholar 

  10. Konno T, Tashiro S, Maeda H, Iwai K, Ogata K, Mochinaga M, Uemura K, Ishimaru Y, Miyauchi Y, Yokoyama I (1983) Treatment of hepatoma with intraarterial administration of oily anticancer agent. Gan to Kagakuryohoo (Jpn J Cancer Chemotherapy) 10:351–357 (in Japanese)

    CAS  Google Scholar 

  11. Jinno K, Yumoto Y, Tokuyama K, Moriwaki S, Maeda H, Konno T (1985) Continuous arterial infusion of anticancer agents and arterial injection of oily anticancer agents. Rinsho Seijin Byo 15: 1657–1665 (in Japanese)

    Google Scholar 

  12. Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor results in enhanced therapeutic effect and X-ray image. Cancer Res 44:2115–2122

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer Japan

About this chapter

Cite this chapter

Konno, T., Maeda, H. (1987). Targeting Chemotherapy of Hepatocellular Carcinoma. In: Okuda, K., Ishak, K.G. (eds) Neoplasms of the Liver. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68349-0_27

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-68349-0_27

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-68351-3

  • Online ISBN: 978-4-431-68349-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics